Yazar "Yıldırım, Mahmut Emre" için listeleme
-
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study
Özdemir, Özlem; Zengel, Baha; Yıldız, Yaşar; Oyan Uluç, Başak; Çabuk, Devrim; Özden, Ercan; Kıvrak Salim, Derya; Paydaş, Semra; Demir, Atakan; Diker, Ömer; Pilancı, Kezban Nur; Uysal Sönmez, Özlem; Vatansever, Sezai; Doğan, İzzet; Gülmez, Ahmet; Çakar, Burcu; Gürsoy, Pınar; Yıldırım, Mahmut Emre; Ayhan, Murat; Karadurmuş, Nuri; Aykan, Musa Barış; Çevik, Gökçen Tuğba; Şakalar, Teoman; Hacıbekiroğlu, İlhan; Belen Gülbağcı, Burcu; Dinçer, Murat; Bayır Garbioğlu, Duygu; Kemal, Yasemin; Nayır, Erdinç; Taşkaynatan, Halil; Yılmaz, Mesut; Avcı, Okan; Sarı, Murat; Çoban, Ezgi; Atcı, Muhammed Mustafa; Aktürk Esen, Selin; Akın Telli, Tuğba; Karataş, Fatih; İnal, Ali; Demir, Hacer; Önal Kalkan, Nurhan; Yılmaz, Cengiz; Taşlı, Funda; Alacacıoğlu, Ahmet (Lippincott, Williams & Wilkins, 07.06.2022)In our study, we aimed to evaluate the pathological response rates and side effect profile of adding pertuzumab to the treatment of HER2+ locally advanced, inflammatory, or early-stage breast cancer. This study was conducted ...
